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Introduction 
Patient choice is nothing new (1) but it is a motif that is 
increasingly mobilised by politicians, policy-makers, and health 
service providers across much of the Western world. Despite its 
global resonance, we want to make the case for considering the 
complexity of the contexts in which patient choice is offered. In 
this paper, we consider research in relation to the domain of 
localised prostate cancer in the UK, specifically to choosing 
treatment after first diagnosis. Before making some 
recommendations for research, the UK context is elaborated 
through a consideration of health policy, which is then related to 
changes in a specific service (the Yorkshire Cancer Centre) and 
research on patients’ experiences of treatment. 
Policy 
The UK White paper entitled, Choosing Health: making health 
choices easier , outlines a commitment to patient choice. More 
specifically, this is a move away from a system that knows how to 
make people healthy to a health service that supports people in 
making choices about their health. Patient treatment decisions are 
more complicated than in other areas of a consumer society. 
Consumer choice in health is problematised through the often 
complex nature of treatment and the limited access patients have to 
relevant information. ‘Patient choice’ is evident in 2008 UK NICE 
(National Institute of Health & Clinical Excellence) guidelines for 
the diagnosis and treatment for prostate cancer where they 
recommend that healthcare professionals should discuss all 
treatment options including the adverse effects of treatments. 
Implementing patient choice in the domain localised prostate 
cancer is not going to be without difficulties. For example, medical 
expertise underlies the development of trust in patient-physician 
communication for men with cancer (2), which may mean that 
patients will still expect health professionals to use their medical 
expertise to decide upon the best course of action. Furthermore, 
there is evidence that physicians view informed patients with 
suspicion alienating those, for example, that use the internet to 
research their condition (3). Nevertheless, informing patients does 
affect their treatment choice (4) and even if findings that informed 
patients appear to be more active in their treatment and have 
reduced levels of psychological distress (5) lack consistency (6) 
informing patients does show positive effects on communication 
processes during periods of treatment decision making. 
Unfortunately, informed patients with localised prostate cancer 
tend to be limited to those that are enthused and literate enough to 
research their condition (7). Although some do argue that 
providing information is an integral part of clinical practice and 
therefore should not be left solely to the patient (8). 
Service Delivery 
UK health services are implementing changes with the intention of 
supporting men diagnosed with localised prostate cancer in making 
the decision that best suits their needs and preferences. The 
centralisation of some specialist services, such as surgery for 
localised prostate cancer, will add another element to treatment 
choice for some men and their carers. We shall introduce one 
service that is implementing choice along side centralisation of 
specialist services to establish how UK health policy is being 
implemented. 
Serving a population of 2.6 million, the Yorkshire Cancer Centre 
(YCC) is one of the largest oncology services outside London. In 
one of the hospitals in the YCC (St. James Hospital, Leeds) major 
surgical and radiotherapy services are provided for patients from 
Leeds, York and Harrogate. Consultations are held in a hospital 
local to the patient. To support patient choice after diagnostic 
results suggest the presence of a localised prostate cancer, the 
consultant will initially discuss treatment options with the patient 
and, where appropriate, the patient’s significant other 
accompanying them at the appointment. The consultation is then 
followed by an appointment with a clinical nurse specialist where 
there is greater opportunity to describe and discuss the different 
treatment options and their associated side-effects. 
The intention of the NICE guidelines is that men with prostate 
cancer decide what treatment they get based on information about 
the choices they could make and that the healthcare service, such 
as YCC, is to support them in this process rather than deciding 
which treatment is most appropriate. As physicians are more likely 
to recommend the treatment options related to their specialism (9), 
the addition of an appointment with a clinical nurse specialist 
should help to minimise this bias and leave patients better 
informed. 
Patients’ Perspective 
There are a number of treatment options for prostate cancer such as 
prostatectomy, brachytherapy, conformal radiotherapy, 
cryotherapy, and high-intensity ultrasound (see Box 1). Treatment 
can even be avoided for ever, or long delayed, as in watchful 
waiting or active surveillance. For those diagnosed with localised 
prostate cancer treatment can have significant side effects (10), 
which means that patient choice policies and service changes 
implementing those policies need to incorporate patients’ 
experiences. 
Treatment may impact on a patient’s sense of identity, particularly 
their masculine identity, and overall wellbeing (11;12). Side effects 
are particularly important for those with a low or medium risk 
diagnosis because there is a possibility that their cancer will not be 
fatal, which could make it more difficult to decide if treatment is 
justifiable. At present there is little evidence to support a survival 
advantage of any particular treatment which would help make 
patient choice clearer (13) and we await the results of a large 
randomised controlled trial (ProtecT) (14). Indeed, the UK 
National Institute for Health and Clinical Excellence (NICE) have 
issued guidance on treatment for localised prostate cancer (15) that 
emphasises the options available. 
There is no doubt that some men will prefer maintaining their 
identity and quality of life to potentially securing longer-term 
survival through treatment with radiotherapy or surgery (16;17). In 
addition, these experiences of treatment are highly differentiated 
(e.g., 18) and even if there are distinct patterns of change in quality 
of life after treatment (19) there is no clear way to predict 
preferences for treatment. Consequently, it is little surprise that 
some argue that attempts to reduce mortality (e.g., 20), should be 
supplemented by developing a better understanding of the lived 
experience of dealing with the impact of prostate cancer and the 
decisions involved (21). 
Importantly, this means supplementing a focus on the 
psychological processes of making treatment decisions (i.e. 
research on ‘decision making’) for an emphasis on the experience 
of periods when decisions about treatment are required. Patients 
place a high priority on the day-to-day practicalities of living with 
cancer (22) and this would seem to include the practical process of 
making decisions about treatment for localised prostate cancer. 
There is good reason for distinguishing between ‘choosing- 
treatment’ and ‘treatment’ periods in the prostate cancer journey 
because, for example, there is evidence that once a treatment 
decision has been made information gathering ends (2) and new 
behaviours are taken up in addition to treatment, such as 
improvements in diet (23). Service changes at YCC could help to 
ensure that all patients are better informed but because choosing 
treatment is so complicated it is important to follow up such 
service changes with an exploration of patients and carers lived 
experience of them. 
Research 
As it is patients and carers who actually go through the period of 
deciding on treatment, they have expertise that will benefit 
research about patient choice not just through an advisory capacity 
but in the process of the investigation. More specifically, exploring 
patients ‘experiences’ requires researchers to make some 
assumptions when deciding which issues to emphasise and how 
best to explore them. There is evidence of a mismatch between the 
cancer research priorities of researchers 
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and patients (22), which suggests that researchers may not be best 
placed to make assumptions about patients’ experiences. 
Furthermore, the first two UK National Cancer Patient Surveys 
(1999-2000 and 2004) found that men with prostate cancer had the 
worst experience of services but research was unable to offer a 
convincing explanation (24), which highlights the importance of 
moving beyond studies that use patients and carers in an advisory 
capacity to investigations where their expertise can benefit the 
process of research. 
While there are attempts to consult patients about their views 
researchers will not be able to resolve this mismatch without 
drawing upon the knowledge and experience of those using cancer 
services (see e.g., 25). Indeed, there is a wealth of activity 
attempting to include patients in the design of research that is 
about patients and their needs (see e.g. www.involve.org.uk), 
which is in line with the philosophy of the discerning consumer in 
UK health policy. Consequently, when attempting to understand 
the experience of making prostate cancer treatment decisions 
patients and carers will be invaluable in directing, designing and 
running such research. 
Summary Box:Policy: Government guidelines (from the National 
Institute for Health and Clinical Excellence; NICE) now 
recommend a number of treatment options (watchful waiting, 
active surveillance, prostatectomy, brachytherapy, and conformal 
radiotherapy) as appropriate for each level of localised prostate 
cancer (low, intermediate and high risk) and says that it is patients 
who must decide between them. 
Service delivery: UK health services are implementing changes 
with the intention of supporting men diagnosed with localised 
prostate cancer in making the decision that best suits their needs 
and preferences. Offering some services, such as surgery for 
localised prostate cancer, at large specialist hospitals (what is 
termed ‘centralisation’) will add another potentially complicating 
aspect to treatment choice for some men and their carers. 
Patient: Treatment choice can be particularly difficult in localised 
prostate cancer because of the uncertainty involved. This means 
that it is important to follow up the policy and service changes with 
an exploration of patients and carers experiences of them. 
Research: When attempting to understand the experience of 
making prostate cancer treatment decisions patients and carers will 
be invaluable in directing, designing and running such research 
Linked InformationInvolve: www.involve.org.ukNICE 
Guideline on the diagnosis and treatment of prostate cancer: 
- Quick Reference Guide: 
http://www.nice.org.uk/nicemedia/pdf/CG58QuickRefGuide.pdf- 
Full Guideline: 
http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf 
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Box 1: Treatment Options for Prostate Cancer 
 Low risk Intermediate risk High risk 
Watchful waiting    
Active surveillance ¥  x 
 
Prostatectomy  ¥ ¥ 
Brachytherapy   X 
Conformal radiotherapy†  ¥ ¥ 
Cryotherapy x‡ x‡ x‡ 
High intensity focused ultrasound x‡ x‡ x‡ 
   Key  
    Treatment option 
   ¥ Preferred treatment 
   x Not Recommended 
* Offer if there is a realistic prospect of long-term disease control 
† Conformal radiotherapy should be given at a minimum dose of 74 Gy (at a maximum of 2 Gy per fraction 
‡ Unless as part of a clinical trial comparing use with established interventions 
Source: National Institute for Health & Clinical Excellence. Prostate Cancer: Diagnosis and 
Treatment. NICE Clinical Guideline 2008: 58: 7 
Radical treatments 
	
